Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 3D map may help surgeons remove lung cancer more accurately

NCT ID NCT06952894

Knowledge-focused Sponsor: Hutom Corp Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a software tool called RUS Lung that creates a 3D model of a patient's lungs from CT scans. Surgeons used it to plan and guide minimally invasive surgery for early-stage lung cancer. The study enrolled 34 adults and checked how well the tool matched the actual tumor location during surgery. The goal was to see if the tool is feasible and helpful, not to prove it improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RUS Lung (a 3D surgical navigation software)
What this could lead to
If successful, this tool could help surgeons perform lung cancer surgery more precisely, potentially improving outcomes and reducing complications.
What could go wrong
This was a small, early-stage study with only 34 participants and no comparison group, so results may not apply broadly. The tool is just a planning aid, not a treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Started

May 2025

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals who were diagnosed with lung caner (tumor size≤3cm) * Individuals aged 19 or older * Individuals who who are able to undergo CT imaging according to the established protocol * Individuals who have voluntarily given written consent to participate in this clinical trial Exclusion Criteria: * Vulnerable subjects * Individuals who who are not able to undergo CT imaging according to the established protocol * Individuals who are expected to have severe adhesions * Individuals who are unable to follow the study procedures and are deemed inappropriate for participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

Contacts and locations

Locations

  • Severance Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.